Yilong Wang | Drug Delivery Systems | Best Researcher Award

Yilong Wang | Drug Delivery Systems | Best Researcher Award

Prof Yilong Wang, Beijing Tiantan Hospital, Capital Medical University, China

Dr. Yilong Wang, Executive Vice President of Beijing Tiantan Hospital, Capital Medical University, is a distinguished neurologist and scientist. With an MD and PhD in Neurology, he has pioneered research in stroke and rare neurological disorders. Author of 301 impactful journal articles and holder of 12 patents, his innovative work spans drug delivery systems and precision medicine. Honored with the 2023 Paul Dudley White International Award, he has also authored several clinical neurology manuals. His cutting-edge contributions, including transcranial drug delivery devices, underscore his commitment to advancing global healthcare. πŸŒπŸ“š

Publication Profile

google scholar

Academic and Professional Background

Professor Yilong Wang πŸŽ“, an accomplished neurologist, earned his MBBS and MSc from North China University of Science and Technology, followed by an MD and PhD in Neurology from Capital Medical University. He completed postdoctoral training at the University of San Francisco πŸŒ‰. Currently serving as Executive Vice President and Chief Scientist at Beijing Tiantan Hospital πŸ₯, Prof. Wang has led groundbreaking research in stroke and rare neurological diseases 🧠. Over the past five years, he has published 72 high-impact papers πŸ“„, holds 12 patents, and made significant strides in precision medicine and drug delivery systems πŸ’Š, earning prestigious accolades like the 2023 Paul Dudley White International Award πŸ†.

Editorial Appointments

Β Professor Yilong Wang πŸ§‘β€βš•οΈ holds prominent editorial roles, serving as the Assistant Editor-in-Chief of Stroke & Vascular Neurology πŸ“š, Deputy Editor-in-Chief of the Chinese Journal of Cerebrovascular Diseases 🧠, and as an editorial board member of the Chinese Journal of Stroke ✍️. His collaborative efforts extend to leading institutions, including the Frontier Medical Interdisciplinary and Translational Center at the National Center for Neurological Disorders 🌐 and the Beijing Brain Science and Brain-Inspired Research Center 🧬. These partnerships underscore his commitment to advancing neurological research and fostering innovation in cerebrovascular and brain science πŸ₯.

Professional Memberships

Professor Yilong Wang πŸ§‘β€βš•οΈ plays key leadership roles in various prestigious organizations. He serves as Vice Chairman of the Expert Committee for the National Health Commission’s Million Disability Reduction Project 🌟, demonstrating his dedication to public health. Prof. Wang is also the Deputy Leader of the Youth Group of the 8th Committee of the Neurology Branch of the Chinese Medical Association 🧠. Additionally, he is the Executive Vice Chairman of the Youth Working Committee of the Chinese Stroke Association πŸ’Ό and Vice Chairman of the Cerebral Small Vessel Disease Branch of the Chinese Stroke Association 🩺, driving innovation in neurological care.

Areas of Research

Professor Yilong Wang πŸ§‘β€βš•οΈ specializes in clinical and translational research on cerebrovascular diseases and rare neurological disorders 🧠, with a focus on interdisciplinary medical-engineering innovations βš™οΈ. His research includes precision medicine for ischemic stroke 🩺, developing technologies for accurate diagnosis and treatment. He pioneers innovative drug delivery systems πŸ’Š, utilizing skull bone marrow-dura-lymphatic pathways to bypass the blood-brain barrier for safe intracranial drug delivery. Prof. Wang also investigates the pathogenesis, diagnostics, and interventions for cerebral small vessel disease and rare neurological disorders 🌐. Additionally, he advances intelligent skull flaps, smart drug delivery systems, and brain-computer interfaces πŸ€–.

Contributions

Professor Yilong Wang πŸ§‘β€βš•οΈ, a renowned neurologist at Beijing Tiantan Hospital πŸ₯, has revolutionized stroke and rare neurological disease research 🧠. Over the past five years, he has published 72 high-impact papers in top journals like NEJM, JAMA, and BMJ πŸ“„ and holds 12 patents, with 2 successfully translated into clinical applications 🌟. His innovations include extending the time window for dual antiplatelet therapy, developing drugs for microcirculation disorders, and pioneering skull-based drug delivery systems to bypass the blood-brain barrier πŸ’Š. Recipient of the 2023 Paul Dudley White International Award πŸ†, Prof. Wang has advanced precision medicine and rare disease research, improving global patient care 🌍.

Research Focus

Professor Yilong Wang is a distinguished researcher focusing on neurology, particularly stroke epidemiology, prevention, and management, and the application of artificial intelligence (AI) in healthcare. His work spans from analyzing stroke prevalence in China to exploring treatment strategies, including antiplatelet therapies and real-world applications of AI in medical practice. With a robust emphasis on stroke prevention, outcomes, and treatment innovation, his contributions bridge advanced research and clinical practice. Wang’s research also addresses the broader implications of healthcare technologies, underscoring their transformative potential. πŸ§ πŸ’ŠπŸ“Š

Publication Top Notes

Artificial intelligence in healthcare: past, present and future

Prevalence, incidence, and mortality of stroke in China: results from a nationwide population-based survey of 480 687 adults

Clopidogrel with aspirin in acute minor stroke or transient ischemic attack

Stroke in China: advances and challenges in epidemiology, prevention, and management

Near-real-time monitoring of global CO2Β emissions reveals the effects of the COVID-19 pandemic

Rivaroxaban for stroke prevention after embolic stroke of undetermined source

Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China: the Chinese Intracranial Atherosclerosis (CICAS) Study

Summer soil drying exacerbated by earlier spring greening of northern vegetation

 

YORINOBU MAEDA | Drug Delivery Systems | Pharmaceutical Advancement Award

YORINOBU MAEDA | Drug Delivery Systems | Pharmaceutical Advancement Award

Prof Dr YORINOBU MAEDA, Fukuyama university, Japan

Prof. Dr. Yorinobu Maeda, Ph.D. (Hiroshima University, 1990), is a renowned expert in drug safety, pharmacokinetics, and infection control. As a professor at Fukuyama University and Drug Safety Director, he has advanced renal function-based dosing and prescription optimization. His contributions have earned him multiple awards, including Best Paper Awards (2001, 2005) and an Academic Contribution Award (2014) from the Japanese Society of Pharmaceutical Health Care and Sciences. With a strong academic and clinical impact, Dr. Maeda is a leading figure in pharmaceutical advancements, ensuring better patient safety and treatment efficacy. πŸ…πŸ”¬

Publication Profile

scopus

Educational and Professional Background

Prof. Dr. Yorinobu Maeda has a distinguished background in pharmaceutical sciences, earning his Ph.D. from Hiroshima University in 1990 πŸŽ“. His expertise spans infection control, hospital pharmacy specialization, and drug safety leadership, reflecting his dedication to pharmaceutical advancements πŸ’Š. With leadership roles in major hospitals πŸ₯ and an esteemed position as a professor at Fukuyama University πŸŽ“, he has made significant academic and practical contributions to the field. His work continues to shape the future of pharmacy, ensuring patient safety and advancing healthcare practices for better medical outcomes πŸŒπŸ”¬.

Contributions to Pharmaceutical Sciences

Prof. Dr. Yorinobu Maeda has made significant contributions to pharmaceutical sciences, particularly in drug safety, pharmacokinetics, and dosage optimization πŸ’ŠπŸ”¬. His research focuses on infection control 🦠, renal function-based dosing πŸ₯, and improving prescription practices, directly enhancing patient safety and treatment efficacy πŸ‘¨β€βš•οΈβœ…. As a Drug Safety Director, he plays a crucial role in advancing pharmaceutical practices, ensuring medications are used effectively and safely. His dedication to optimizing drug therapy and refining medical protocols continues to have a lasting impact on healthcare, improving outcomes for patients worldwide πŸŒπŸ’‰.

Awards and Recognitions

Prof. Dr. Yorinobu Maeda has made remarkable contributions to the field of pharmaceutical healthcare, earning numerous prestigious accolades from the Japanese Society of Pharmaceutical Health Care and Sciences. His achievements include the Best Paper Awards in 2001 and 2005 πŸ†, as well as the esteemed Academic Contribution Award in 2014 πŸŽ“. These honors highlight his dedication to advancing research and implementing pharmacokinetic principles to enhance patient safety and care 🩺. Dr. Maeda’s work stands as a testament to his unwavering commitment to improving healthcare standards and fostering innovation in pharmaceutical sciences. 🌟

Research Focus

Professor Dr. Yorinobu Maeda is an eminent researcher specializing in pharmaceutical sciences, with a primary focus on drug bioavailability, prodrug development, and therapeutic drug monitoring. His work spans areas such as drug absorption, small intestinal bacterial overgrowth diagnosis, and managing adverse drug reactions. Notable research includes the impact of metal ions on drug efficacy and innovative prodrug strategies. Through collaborative studies, he contributes to optimizing drug delivery systems and clinical pharmacotherapy, enhancing patient safety and treatment outcomes. πŸ§ͺπŸ’Š

Publication Top Notes

5-Aminosalicylic Acid Distribution into the Intestinal Membrane Along the Gastrointestinal Tract After Oral Administration in Rats

Development and Evaluation of EDTA-Treated Rabbits for Bioavailability Study of Chelating Drugs Using Levofloxacin, Ciprofloxacin, Hemiacetal Ester Prodrugs, and Tetracycline

Diagnosis by Microbial Culture, Breath Tests and Urinary Excretion Tests, and Treatments of Small Intestinal Bacterial Overgrowth

Ester Prodrugs of Levofloxacin to Prevent Chelate Formation in Presence of Aluminium Ion

Study on the method to avoid infusion‑site adverse events following chemotherapeutic treatment with epirubicin and fosaprepitant using immortalized human umbilical vein endothelial cells

Effect of aluminium ion on bioavailability of levofloxacin following oral administration of cilexetil ester of levofloxacin as prodrug in rats